<table cellpadding="0pt" width="531pt" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2. Effects of Other Drugs on MOVANTIK</caption>
<col width="28%"></col>
<col width="31%"></col>
<col width="41%"></col>
<tbody>
<tr>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Concomitant Agent</content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Mechanism of Action</content>
</paragraph>
</td>
<td stylecode="Rrule Botrule Toprule " valign="top">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">Clinical Recommendation</content>
</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">CYP3A4 Inhibitors</content>
</paragraph>
</td>
<td stylecode="Rrule Botrule " valign="middle"></td>
<td stylecode="Rrule Botrule " valign="middle"></td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)</item>
</list>
</td>
<td rowspan="2" stylecode="Rrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Increase plasma naloxegol concentrations and may increase the risk of adverse reactions [<content stylecode="italics">see  <content stylecode="underline">
<linkhtml href="#ID_6595e8fc-3b68-4511-b001-58f225054a6a">Clinical Pharmacology (12.3)</linkhtml>
</content>
</content>]<content stylecode="italics">.  </content>
</item>
</list>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Use with strong CYP3A4 inhibitors is contraindicated [<content stylecode="italics">see <content stylecode="underline">
<linkhtml href="#ID_daa6c21f-9217-42d7-b9b4-a6af7727af20">Contraindications (4)</linkhtml>
</content>
</content>].</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil)</item>
</list>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Avoid use with moderate CYP3A4 inhibitors; if unavoidable, decrease the dosage of MOVANTIK to 12.5 mg once daily and monitor for adverse reactions [<content stylecode="italics">see  <content stylecode="underline">
<linkhtml href="#ID_496eacd9-d585-4048-af5d-006ec7953c4a">Dosage and Administration (2.4)</linkhtml>
</content>
</content>].</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Weak CYP3A4 inhibitors (e.g., quinidine, cimetidine)</item>
</list>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Clinically significant increases in naloxegol concentrations are not expected.  </item>
</list>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>No dosage adjustments are necessary. </item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Grapefruit or grapefruit juice<footnote id="_Ref399216725">The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation dependent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation was used (e.g., high dose, double strength) or as a “moderate CYP3A inhibitor” when another preparation was used (e.g., low dose, single strength).</footnote>
</item>
</list>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Can increase plasma naloxegol concentrations. </item>
</list>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Avoid consumption of grapefruit or grapefruit juice during treatment with MOVANTIK [<content stylecode="italics">see  <content stylecode="underline">
<linkhtml href="#ID_57663702-9281-4245-b143-eb34904f5ba1">Dosage and Administration (2.1)</linkhtml>
</content>
</content>].</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="ordered">
<item>
<caption> </caption>
<content stylecode="bold">CYP3A4 Inducers</content>
</item>
</list>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle"></td>
<td stylecode="Rrule Lrule Botrule " valign="middle"></td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John’s Wort)</item>
</list>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Significantly decrease plasma naloxegol concentrations and may decrease the efficacy of MOVANTIK [<content stylecode="italics">see  <content stylecode="underline">
<linkhtml href="#ID_6595e8fc-3b68-4511-b001-58f225054a6a">Clinical Pharmacology (12.3)</linkhtml>
</content>
</content>].    </item>
</list>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Use with strong CYP3A4 inducers is not recommended<content stylecode="italics">.</content>
</item>
</list>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Other Drug Interactions</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle"></td>
<td stylecode="Rrule Lrule Botrule " valign="middle"></td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Other opioid antagonists</item>
</list>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Potential for additive effect of opioid receptor antagonism and increased risk of opioid withdrawal.</item>
</list>
</td>
<td stylecode="Rrule Botrule " valign="middle">
<list listtype="unordered">
<item>
<caption>•</caption>Avoid use of MOVANTIK<content stylecode="bold"></content>with another opioid antagonist.</item>
</list>
</td>
</tr>
</tbody>
</table>